This week, it sold some brands to Charterhouse Capital Partners’ Cooper-Vemedia drugs manufacturing arm for 158 million euros.” hemophilia specialist Bioverativ, but also selling off some assets. Reuters notes, “Sanofi has been reshaping its business in recent months, spending more than $16 billion to buy biotech company Ablynx and U.S. Advent, a private equity firm, will acquire the company for 1.9 billion euros, or about $2.4 billion (U.S.). The deal is expected to wrap by the end of this year. Paris-based Sanofi has agreed to sell its generics division, Zentiva, to Advent International.
Sanofi to Sell its Generic Division to Advent for $2.4 Billion
